RT Journal
T1 Error in financial disclosure in: Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the pediatric ocd treatment study ii (pots ii) randomized controlled trial
JF JAMA
JO JAMA
YR 2012
FD April 25
VO 307
IS 16
SP 1694
OP 1694
DO 10.1001/jama.2012.536
UL http://dx.doi.org/10.1001/jama.2012.536
AB 
Error in Financial Disclosure.  In the Original Contribution entitled “Cognitive Behavior Therapy Augmentation of Pharmacotherapy in Pediatric Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study II (POTS II) Randomized Controlled Trial,” published in the September 21, 2011, issue of JAMA (2011;306[11]:1224-1232), the financial disclosure for Dr March was incorrect. It should have read: “Dr March reported that he is a scientific advisor for Pfizer, Lilly, Bristol-Myers-Squib, and Shire Pharmaceuticals; receives research support from Pfizer, is a member of the data safety and monitoring boards for Otsuka and Lilly, is an equity holder in MedAvante; and receives royalties from MultiSystems for the Multidimensional Anxiety Scale for Children and for books from Guilford and from Oxford University Press.”